Tuberculosis, Pulmonary
Information
- Disease name
- Tuberculosis, Pulmonary
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04734652 | Active, not recruiting | Phase 2 | INSTI's For The Management of HIV-associated TB | February 18, 2022 | August 31, 2024 |
| NCT04179500 | Active, not recruiting | Phase 2 | A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Volunteers | September 16, 2021 | August 30, 2024 |
| NCT04919239 | Active, not recruiting | Phase 2 | Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB) | September 22, 2021 | March 2025 |
| NCT05047055 | Active, not recruiting | Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients | March 15, 2022 | March 31, 2025 | |
| NCT03512249 | Active, not recruiting | Phase 2 | Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence | January 31, 2019 | March 30, 2024 |
| NCT02715271 | Active, not recruiting | Study of TB Lesions Obtained in Therapeutical Surgery | September 2016 | July 2025 | |
| NCT05889364 | Active, not recruiting | AI-based System for Lung Tuberculosis Screening: Diagnostic Accuracy Evaluation | February 1, 2018 | December 30, 2023 | |
| NCT05190146 | Active, not recruiting | Epidemiologic Study to Assess the IGRA Positivity in Populations With a High TB Burden | December 20, 2021 | September 30, 2024 | |
| NCT01162486 | Completed | Phase 1 | Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers | April 2010 | March 2011 |
| NCT01218217 | Completed | Phase 2 | Early Bactericidal Activity (EBA) of SQ109 in Adult Subjects With Pulmonary TB | November 2010 | May 2012 |
| NCT01364324 | Completed | Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients | September 2010 | June 2020 | |
| NCT01785186 | Completed | Phase 2 | Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design | April 2013 | March 2015 |
| NCT01945905 | Completed | N/A | Cost-effectiveness of Two Forms of DOTS in a Demonstration Area of the DOTS Strategy in Colombia | December 2009 | September 2014 |
| NCT02153528 | Completed | Phase 3 | Optimization of the TB Treatment Regimen Cascade | November 2014 | August 1, 2017 |
| NCT02589782 | Completed | Phase 2/Phase 3 | Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) | January 2017 | August 5, 2022 |
| NCT06171646 | Completed | N/A | Effect of Breathing Exercise on Fatigue in Patients With Pulmonary Tuberculosis | June 1, 2023 | September 30, 2023 |
| NCT05899400 | Completed | A Study to Validate and Improve an Automated Image Analysis Algorithm to Detect Tuberculosis in Sputum Smear Slides | September 15, 2019 | December 31, 2022 | |
| NCT00140309 | Completed | Phase 2 | TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment | July 2003 | December 2005 |
| NCT04721795 | Completed | Phase 2/Phase 3 | Treating Tuberculosis With the Lipid Lowering Drug Atorvastatin in Nigeria(ATORvastatin in Pulmonary TUBerculosis) | January 19, 2021 | June 30, 2022 |
| NCT00419068 | Completed | Phase 3 | Trial of Adjunctive Vitamin D in Tuberculosis Treatment | January 2007 | September 2009 |
| NCT00495339 | Completed | Phase 4 | MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis | June 2007 | |
| NCT00567151 | Completed | Co-Infection of NTM in Patients With Smear Positive Pulmonary TB | December 2007 | December 2008 | |
| NCT00685360 | Completed | Phase 2 | A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB) | May 8, 2008 | June 11, 2010 |
| NCT00939419 | Completed | Phase 4 | The Effectiveness of Health Facility-based and Community-based Care for Tuberculosis | January 2005 | February 2007 |
| NCT01130311 | Completed | N/A | Replacement of Vitamin D in Patients With Active Tuberculosis | October 2009 | December 2010 |
| NCT03822156 | Completed | Clinical Analysis of the Patients With Cavitary Pulmonary TB and Endobronchial TB in the PPM-UUH Cohort | January 1, 2010 | June 30, 2018 | |
| NCT04973371 | Completed | N/A | Acceptability and Feasibility of Home-based TB Testing | July 1, 2018 | June 30, 2019 |
| NCT04938596 | Completed | N/A | Airborne Preventive Measures to Reduce New TB Infections in Household Contacts | October 4, 2021 | March 30, 2024 |
| NCT04874948 | Completed | Phase 1 | Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment | September 21, 2021 | October 15, 2021 |
| NCT04865536 | Completed | Phase 1 | Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects | February 16, 2021 | March 25, 2022 |
| NCT04079400 | Completed | Microbiome in Pulmonary Tuberculosis, Non-tuberculous Mycobacterial Pulmonary Diseases, Lung Cancer and Hemoptysis | December 1, 2016 | April 11, 2019 | |
| NCT04122404 | Completed | N/A | POC Strategies to Improve TB Care in Advanced HIV Disease | October 14, 2019 | January 30, 2022 |
| NCT00054769 | Completed | Diagnosing Tuberculosis in HIV Infected Children in Peru | March 2002 | February 2007 | |
| NCT04848246 | Completed | N/A | Effect of Smoking Cessation on Tuberculosis Treatment Outcomes | November 6, 2017 | October 15, 2019 |
| NCT04493671 | Completed | Phase 1 | Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults | June 8, 2020 | November 15, 2022 |
| NCT04682990 | Completed | N/A | DIAGNOSIS of PULMONARY TUBERCULOSIS Through HUMAN BREATH (TBENOSE) | January 5, 2021 | December 5, 2021 |
| NCT00004444 | Completed | N/A | Pilot Randomized Study of Paromomycin (Aminosidine) vs Streptomycin for Uncomplicated Pulmonary Tuberculosis | November 1994 | January 2001 |
| NCT05640648 | Completed | N/A | Human-centered Design and Communities of Practice to Improve Delivery of Home-based Tuberculosis Contact Investigation in Uganda | March 7, 2022 | October 26, 2023 |
| NCT05526911 | Completed | Phase 1 | A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults | July 20, 2022 | August 28, 2022 |
| NCT03044158 | Completed | N/A | GeneXpert Performance Evaluation for Linkage to Tuberculosis Care | October 22, 2018 | July 31, 2022 |
| NCT03072576 | Completed | Accuracy and Feasibility of Xpert Ultra | March 2016 | October 2017 | |
| NCT03086486 | Completed | Phase 3 | Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis | November 21, 2017 | February 8, 2022 |
| NCT03160638 | Completed | Phase 2 | Azithromycin as Host-directed Therapy for Pulmonary Tuberculosis | February 1, 2018 | May 22, 2022 |
| NCT03174184 | Completed | Phase 2 | Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB | August 23, 2017 | May 13, 2022 |
| NCT03199313 | Completed | Phase 1 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid | September 26, 2017 | December 16, 2017 |
| NCT03199339 | Completed | Phase 1 | A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371 | August 29, 2017 | July 8, 2018 |
| NCT03271567 | Completed | Nanodisk-MS Assay for the Diagnosis of Active Pulmonary and Extrapulmonary Tuberculosis in Hospitalized Patients | September 28, 2017 | December 31, 2019 | |
| NCT05258877 | Completed | Pharmacokinetics of Ethionamide and Ethionamide Sulfoxide in Patients Established on Treatment for Tuberculosis. | June 10, 2022 | September 30, 2023 | |
| NCT03338621 | Completed | Phase 2/Phase 3 | Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients | July 30, 2018 | June 10, 2022 |
| NCT05122624 | Completed | N/A | A Clinical Risk Score for Early Management of TB in Uganda | November 10, 2021 | February 29, 2024 |
| NCT03423030 | Completed | Phase 1 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-vivo Antitubercular Activity of PBTZ169 Formulation | December 5, 2017 | March 28, 2018 |
| NCT03474198 | Completed | Phase 2/Phase 3 | Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis | March 21, 2018 | January 20, 2022 |
| NCT05073965 | Completed | N/A | Vitamin D Supplementation Effect In Children With Pulmonary Tuberculosis Treatment | December 1, 2020 | July 30, 2021 |
| NCT05065905 | Completed | Phase 1/Phase 2 | Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis | January 19, 2006 | April 6, 2006 |
| NCT03590600 | Completed | Phase 1 | A Single Ascending Dose Study of BTZ043 | June 7, 2018 | March 5, 2019 |
| NCT03712709 | Completed | Clinical Evaluation of the Truenat Point-of-care Tuberculosis Diagnostic Test | March 12, 2019 | July 9, 2020 | |
| NCT03728725 | Completed | Xpert MTB/XDR Clinical Evaluation Trial | July 11, 2019 | August 18, 2020 | |
| NCT04995406 | Completed | Validating the Use of Blood Transcriptomic Signatures for the Diagnosis of Active Pulmonary Tuberculosis | January 3, 2022 | December 31, 2023 | |
| NCT03758612 | Completed | Phase 1 | A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults | January 16, 2019 | March 14, 2020 |
| NCT03776500 | Completed | Phase 1 | Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBTZ169 in Multiple Dosing | February 21, 2019 | March 20, 2020 |
| NCT05048485 | Enrolling by invitation | Tuberculosis - Learning the Effect of Parasites and Reinforcing Diets | April 9, 2022 | December 2025 | |
| NCT05477966 | Not yet recruiting | A Retrospective Cohort Study to Develop Markers for TB Severity and Treatment Progress | July 18, 2022 | July 18, 2023 | |
| NCT05454345 | Not yet recruiting | Phase 3 | Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment | October 1, 2022 | June 30, 2026 |
| NCT06253715 | Not yet recruiting | Phase 3 | Shortened Regimen for Drug-susceptible TB in Children | September 30, 2024 | September 30, 2027 |
| NCT04485156 | Not yet recruiting | Phase 3 | Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3) | September 2020 | December 2026 |
| NCT06205589 | Not yet recruiting | Phase 2 | Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB | October 15, 2024 | April 1, 2029 |
| NCT04856644 | Not yet recruiting | Phase 3 | Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB | May 1, 2021 | December 31, 2024 |
| NCT06392594 | Not yet recruiting | Performance of Xpert MTB/RIF and XDR Assay for Diagnosis of Pulmonary Tuberculosis and Resistant Pulmonary TB | April 23, 2024 | May 23, 2025 | |
| NCT06409780 | Not yet recruiting | N/A | Comparative Efficacy of CUS, CXR and CAD in TB Diagnosis in LMIC | May 5, 2024 | April 30, 2025 |
| NCT05981495 | Not yet recruiting | Clinical Evaluation of the NanoDetect-TB Mycobacterium Tuberculosis Detection Kit for the Diagnosis of Tuberculosis Disease | August 2023 | December 2024 | |
| NCT06441006 | Not yet recruiting | Phase 3 | Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis | November 1, 2024 | November 30, 2029 |
| NCT05664568 | Recruiting | Phase 2 | The BLAST- 1 Trial - Cephalexin+Amoxicillin-clavulanate for Tuberculosis | March 15, 2023 | December 2024 |
| NCT04147286 | Recruiting | Phase 2/Phase 3 | Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion | July 14, 2020 | June 30, 2026 |
| NCT04575519 | Recruiting | Phase 2 | Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis | March 4, 2021 | June 2025 |
| NCT04752592 | Recruiting | N/A | Evaluation of a Rapid Point-of-Care Serological Triage Test for Active TB | September 21, 2021 | December 31, 2025 |
| NCT04844502 | Recruiting | N/A | Cardiopulmonary Function and Quality of Life in Pulmonary Tuberculosis | April 7, 2021 | December 1, 2023 |
| NCT05007821 | Recruiting | Phase 2 | Linezolid Dosing Strategies in Drug-Resistant TB | August 11, 2022 | November 14, 2025 |
| NCT05236452 | Recruiting | N/A | Effect of Integrating Traditional Tuberculosis Care With Modern Health Care on Case Detection | July 1, 2022 | December 30, 2023 |
| NCT05268380 | Recruiting | Collision of Three Global Pandemics: the Effect of Tuberculosis and HIV on the Epidemiological, Clinical, Virological and Immunological Trajectory of COVID-19 in Botswana and Namibia | August 1, 2022 | December 31, 2023 | |
| NCT05285202 | Recruiting | N/A | Clinic-based Versus Hotspot-focused Active TB Case Finding | June 1, 2022 | January 31, 2027 |
| NCT05325125 | Recruiting | Childhood TB Sequel | March 29, 2022 | June 2024 | |
| NCT05401071 | Recruiting | Phase 2/Phase 3 | Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T) | January 13, 2023 | November 1, 2027 |
| NCT05455112 | Recruiting | Phase 2 | Safety and Efficacy of RUTI® With the Standard of Treatment for Tuberculosis | October 29, 2022 | December 2024 |
| NCT05539014 | Recruiting | Tuberculosis Cohort Avicenne Hospital | January 18, 2023 | December 15, 2027 | |
| NCT05556746 | Recruiting | Phase 2 | Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB | November 24, 2023 | January 2027 |
| NCT05756582 | Recruiting | Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students | November 17, 2021 | December 15, 2026 | |
| NCT05766267 | Recruiting | Phase 2/Phase 3 | Short-course Regimens for the Treatment of Pulmonary Tuberculosis | November 21, 2023 | December 31, 2026 |
| NCT05926466 | Recruiting | Phase 2 | BTZ-043 Dose Evaluation in Combination and Selection | September 21, 2023 | August 2024 |
| NCT06057519 | Recruiting | Phase 3 | Pragmatic Optimized Rifampicin Trial | January 16, 2024 | December 31, 2025 |
| NCT06084715 | Recruiting | The INSTITUT Study | September 7, 2023 | December 2025 | |
| NCT06159023 | Recruiting | N/A | Conventional Bronchoscope With BAL vs. Thin Bronchoscope With BW to Diagnose Pulmonary TB | December 15, 2023 | December 31, 2025 |
| NCT04694586 | Suspended | Phase 2 | Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide | November 30, 2022 | May 31, 2026 |
| NCT01381757 | Terminated | Utility of MODS for Diagnosis of MDR-TB and Second-Line Antituberculous Drug Susceptibility Testing in Mali | May 31, 2011 | March 5, 2013 | |
| NCT04150367 | Terminated | Efficacy and Safety of Intravenous Treatment of Tuberculosis | March 3, 2017 | July 14, 2018 | |
| NCT03028129 | Terminated | Phase 4 | Prevention of Tuberculosis in Prisons | September 4, 2017 | August 10, 2019 |
| NCT03302949 | Terminated | N/A | Treating Tuberculosis Wasting With a High-protein Supplement | August 1, 2017 | January 30, 2023 |
| NCT04783727 | Terminated | N/A | PredictEndTB Signature for Individualizing Treatment in Multidrug-Resistant Tuberculosis | April 1, 2021 | November 1, 2022 |
| NCT02901288 | Unknown status | Phase 4 | Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis | August 2016 | December 2018 |
| NCT02776150 | Unknown status | Probe Melting Technology for Rapid Detection of Drug Resistant Tuberculosis | May 2016 | June 2019 | |
| NCT01638520 | Unknown status | Phase 2 | Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Therapy for Pulmonary Tuberculosis | June 2012 | July 2017 |
| NCT05388448 | Unknown status | Phase 2 | EBA, Safety and Tolerability of Sanfetrinem Cilexetil | April 21, 2022 | December 1, 2023 |
| NCT02768909 | Unknown status | N/A | Diagnostic Trial to Validate the Use of the E-Nose in Pulmonary TB | January 2015 | February 2017 |
| NCT03251196 | Unknown status | TB Sequel: Pathogenesis and Risk Factors of Long-term Sequelae of Pulmonary TB | September 22, 2017 | June 30, 2022 | |
| NCT01525134 | Unknown status | N/A | Feasibility of a Lateral Flow Urine Lipoarabinomannan (LAM) Test for Diagnosis of Tuberculosis | January 2011 | April 2012 |
| NCT03220464 | Unknown status | N/A | Early Diagnosis of Active Tuberculosis Using Ultra Low-dose Chest CT | June 20, 2017 | April 30, 2020 |
| NCT01395654 | Unknown status | Phase 4 | Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment | July 2011 | December 2015 |
| NCT02972697 | Unknown status | Phase 1 | Evaluation of 11C-acetate PET Imaging as a Novel Approach to Detecting Pathology in Pulmonary TB | November 2016 | |
| NCT04766307 | Unknown status | Phase 4 | A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2 | July 20, 2016 | December 31, 2021 |
| NCT02967666 | Unknown status | Phase 1 | Evaluation of PET/MRI Using a Somatostatin Analog Tracer as a Novel Approach to Detecting Pathology in High Risk TB-exposed Contacts | November 2016 | |
| NCT04232618 | Unknown status | Point-of-care Triage Test for Active Tuberculosis | November 5, 2020 | March 2024 | |
| NCT04074369 | Unknown status | Evaluation of CRISPR-based Test for the Rapid Identification of TB in Pulmonary Tuberculosis Suspects | May 1, 2019 | October 30, 2019 | |
| NCT04055584 | Unknown status | PCR Techniques of Dried Sputum Using a Spotcard | July 2, 2019 | December 31, 2021 | |
| NCT03967353 | Unknown status | N/A | Study on the Management Model of "Home Treatment" for Tuberculosis Patients | March 22, 2018 | December 2022 |
| NCT03519425 | Unknown status | N/A | A Pragmatic Randomised Study to Optimise Screening, Prevention and Care for Tuberculosis in Malawi | November 15, 2018 | June 2020 |
| NCT03478033 | Unknown status | N/A | Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis | April 15, 2018 | December 31, 2020 |
| NCT03416309 | Unknown status | Personalization of AntiTB Treatment: Evaluation of Pharmacological Determinants of Treatment Response | May 25, 2017 | February 28, 2022 | |
| NCT05215990 | Unknown status | Phase 1/Phase 2 | Efficacy of Metformin for Sputum Conversion in Patients With Active Pulmonary Tuberculosis | January 15, 2022 | March 31, 2023 |
| NCT01693224 | Unknown status | N/A | Feasibility of a Lateral Flow Urine LAM Test for Diagnosis of Tuberculosis in South Africa | April 2011 | February 2013 |
| NCT03281226 | Unknown status | Phase 2 | RIPE vs RIPE Plus N-acetylcysteine in Patients With HIV/TB Co-infection | December 7, 2016 | December 2019 |
| NCT04968886 | Unknown status | TuBerculosis Viability Interregional Study and Agreement on Biological Tests | September 2022 | December 2023 | |
| NCT02653404 | Unknown status | IGRA and Mantoux Response in Children With Suspected Latent or Active TB Infection | April 2015 | December 2020 | |
| NCT03702738 | Unknown status | Phase 2 | Adjunctive NAC in Adult Patients With Pulmonary Tuberculosis | March 1, 2019 | December 31, 2021 |
| NCT03732014 | Withdrawn | Bronchial Washings in Sputum Scarce Cases of Pulmonary Tuberculosis | January 2, 2019 | November 30, 2019 | |
| NCT03941496 | Withdrawn | Phase 1/Phase 2 | Azacytidine During Anti-tuberculosis Therapy | October 2022 | May 2023 |
| NCT03547479 | Withdrawn | N/A | VDOT and Mobile Payments in Cambodia | May 2019 | December 2019 |
| NCT03862248 | Withdrawn | Phase 3 | Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More | September 30, 2019 | October 1, 2022 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D014397